1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(MARK ONE)
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
- ---- EXCHANGE ACT OF 1934.
For the quarterly period ended June 30, 1998
OR
TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
- ---- SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
COMMISSION FILE NUMBER 1-10113
HALSEY DRUG CO., INC.
(Exact name of registrant as specified in its charter)
New York 11-0853640
(State or other Jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
695 N. Perryville Rd.
Rockford, IL 61107
(Address of Principal executive offices) (Zip Code)
(815) 399 - 2060
(Registrant's telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last
report.)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 50 days.
YES X NO
----- -----
As of August 13, 1998 the registrant had 13,794,756 Shares of Common Stock, $.01
par value, outstanding.
2
HALSEY DRUG CO., & SUBSIDIARIES
INDEX
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited) Page #
Condensed Consolidated Balance Sheets- 3
June 30, 1998 and December 31, 1997
Condensed Consolidated Statements of 5
Operations - Three and six months ended June 30, 1998
and June 30, 1997
Consolidated Statements of Cash 6
Flows - Six months ended June 30, 1998
and June 30, 1997
Consolidated Statements of Stockholders' 7
Equity - Six months ended June 30, 1998
Notes to Condensed Consolidated Financial 8
Statements
Item 2. Management's Discussion and Analysis of Financial 10
Condition and Results of Operations
PART II OTHER INFORMATION
Item 1. Legal Proceedings 14
Item 2. Changes in Securities 14
Item 4. Submission of Matters to a Vote of Security Holders 15
Item 6. Exhibits and Reports on Form 8-K 16
SIGNATURES 17
2
3
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
HALSEY DRUG CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands)
JUNE 30, 1998 DEC. 31, 1997
------------- -------------
(UNAUDITED)
CURRENT ASSETS
Cash and cash equivalents $ 3,614 $ 26
Accounts Receivable - trade, net of
allowances for doubtful accounts of $50
and $ 542 at June 30, 1998 and December
31, 1997, respectively 927 62
Other receivable -- --
Inventories 5,109 2,456
Prepaid insurance and other current assets 160 274
------- -------
Total current assets 9,810 2,818
PROPERTY PLANT & EQUIPMENT, NET 4,698 4,630
OTHER ASSETS 3,710 219
------- -------
TOTAL ASSETS $18,218 $ 7,667
======= =======
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE STATEMENTS
3
4
HALSEY DRUG CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands)
JUNE 30, 1998 DEC. 31, 1997
------------- -------------
(UNAUDITED)
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
CURRENT LIABILITIES
Bank overdraft $ -- $ 159
Due to banks -- 2,476
Notes payable 3,062 4,825
Convertible subordinated debentures -- 2,244
Department of justice settlement 300 200
Accounts payable 1,358 6,086
Accrued expenses 5,383 7,644
Deferred gain -- 1,900
-------- --------
Total current liabilities 10,103 25,534
LONG-TERM DEBT 30,125 1,990
CONTINGENCIES __ __
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock - $.01 par value; authorized 142 140
40,000,000, shares; issued and outstanding
14,217,051 shares at June 30,1998 and
14,029,713 shares at December 31, 1997
Additional paid-in capital 28,169 25,489
Accumulated deficit (49,332) (44,497)
-------- --------
(21,021) (18,868)
Less: Treasury stock - at cost -(439,603 (989) (989)
shares at June 30, 1998 and December 31, -------- --------
1997)
Total stockholders' equity (deficit) (22,010) (19,857)
-------- --------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 18,218 $ 7,667
======== ========
The accompanying notes are an integral part of these statements
4
5
HALSEY DRUG CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(Amounts in thousands except per share data)
June 30
------------------------------------------------------------------
For the six months ended For the three months ended
------------------------------ ------------------------------
1998 1997 1998 1997
------------ ------------ ------------ ------------
Net sales ................... $ 4,116 $ 5,052 $ 2,221 $ 2,209
Cost of goods sold .......... 6,290 7,355 2,958 3,250
------------ ------------ ------------ ------------
Gross profit (loss) ...... (2,174) (2,303) (737) (1,041)
Research & development ...... 452 483 231 318
Selling, general and
administrative expenses ..... 3,208 2,682 1,621 1,222
------------ ------------ ------------ ------------
Loss from operations ..... (5,834) (5,468) (2,589) (2,581)
66
Other income ................ 1,968 -- --
Interest expense, net ....... 969 537 531 277
------------ ------------ ------------ ------------
Loss before income taxes .... (4,835) (6,005) (3,054) (2,858)
------------ ------------ ------------ ------------
Provision for income taxes .. -- -- -- --
------------ ------------ ------------ ------------
Net loss .................... $ (4,835) $ (6,005) $ (3,054) $ (2,858)
============ ============ ============ ============
Net loss per common share ... (0.35) (0.45) (0.22) (0.21)
============ ============ ============ ============
Average number of outstanding
shares 13,756,600 13,246,077 13,777,258 13,515,063
============ ============ ============ ============
The accompanying notes are an integral part of these statements
5
6
HALSEY DRUG CO., AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Amounts in thousands SIX MONTHS ENDED
June 30
1998 1997
-------- --------
Cash flows from operating activities
Net loss ..................................................... $ (4,835) $ (6,005)
Adjustments to reconcile net loss to net cash used in operating
activities .................................................... 816 854
Depreciation and amortization
Provision for loss on accounts receivable ................ (492) --
Loss on disposal of assets ............................... 93 --
Changes in assets and liabilities
Accounts receivable ................................... (373) (404)
Other receivable ...................................... -- 1,000
Inventories ........................................... (2,653) (714)
Prepaid insurance and other current assets ............ 114 (153)
Accounts payable ...................................... (4,728) (329)
Deferred gain ......................................... (1,900) --
Accrued expenses ...................................... (2,438) 2,022
-------- --------
Total adjustments ..................................... (11,561) 2,276
-------- --------
Net cash used in operating activities .............. (16,396) (3,729)
-------- --------
Cash flows from investing activities
Capital expenditures ..................................... (724) 36
(Decrease) increase in other assets ...................... (896) (3)
-------- --------
Net cash used in investing activities ................. (1,620) (33)
-------- --------
Cash flows from financing activities
Increase (decrease) in notes payable ..................... (1,763) 3,900
Decrease in amount due to banks .......................... (2,476) (719)
Issuance of common stock for payment of interest ......... 202 112
Exercise of warrants of convertible debentures ........... -- 72
Exercise of stock options ................................ -- 305
Issuance of convertible subordinated debentures .......... 25,800 --
Proceeds from issuance of treasury stock ................. -- 100
Increase (decrease) in bank overdraft .................... (159) 10
-------- --------
Net cash provided by financing activities ............. 21,604 3,780
-------- --------
Net (decrease) increase in cash and cash equivalents ..... 3,588 84
Cash and cash equivalents at beginning of period .............. 26 118
-------- --------
Cash and cash equivalents at end of period .................... $ 3,614 $ 202
======== ========
Supplemental disclosure of noncash activities:
For the 6 months ended June 30, 1998
The Company issued 110,658 shares of common stock as payment for an outstanding
note payable in the amount of $214,000 and accrued interest of $1,782.
The Company issued 76,680 shares of common stock as payment for $201,886 of
accrued interest.
The accompanying notes are an integral part of these statements
6
7
HALSEY DRUG CO., INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY(DEFICIT)
SIX MONTHS ENDED JUNE 30, 1998
(AMOUNTS IN THOUSANDS EXCEPT PER SHARE DATA)
(UNAUDITED)
COMMON STOCK, $.01 PAR VALUE ADDITIONAL TREASURY STOCK, AT COST
---------------------------- PAID-IN ACCUMULATED -------------------------
SHARES AMOUNT CAPITAL DEFICIT SHARES AMOUNT TOTAL
---------- ----------- ----------- ----------- -------- ----------- -----------
Balance January 1, 1998 14,029,713 $ 140 $ 25,489 $ (44,497) (439,603) $ (989) $ (19,857)
Net Loss for the six
months ended June 30, 1998 (4,835) (4,835)
Conversion of notes
payable 110,658 2 215 217
Issuance of shares as
payment of interest 76,680 -- 202 202
Deferred debt discount on
warrants issued with
convertible debentures 2,263 2,263
---------- ----------- ----------- ----------- -------- ----------- -----------
Balance at June 30, 1998 14,217,051 $ 142 $ 28,169 $ (49,332) (439,603) $ (989) $ (22,010)
========== =========== =========== =========== ======== =========== ===========
The accompanying notes are an integral part of this statement
7
8
HALSEY DRUG CO., INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 1 - Basis of Presentation
The accompanying unaudited condensed consolidated financial statements
of Halsey Drug Co., Inc. and subsidiaries (the "Company") have been prepared in
accordance with generally accepted accounting principles for interim financial
information and with the instructions to Form 10-Q and Rule 10-01 of Regulation
S-X. Accordingly, they do not include all of the information and footnotes
required by generally accepted accounting principles for complete financial
statements. In the opinion of management, all adjustments considered necessary
to present fairly the financial position, results of operations and changes in
cash flows for the six months ended June 30, 1998 have been made. The results of
operations for the six months period ended June 30, 1998 are not necessarily
indicative of the results that may be expected for the full year ended December
31, 1998. The unaudited condensed consolidated financial statements should be
read in conjunction with the consolidated financial statements and footnotes
thereto for the year ended December 31, 1997 included in the Company's Annual
Report on Form 10-K filed with the Securities and Exchange Commission.
As of June 30, 1998, the Company had a working capital deficiency of
approximately $293,000 and an accumulated deficit of approximately $49,332,000.
The Company incurred a loss of approximately $4,835,000 during the six months
ended June 30, 1998.
Note 2 - Inventories
Inventories consists of the following:
(Amounts in thousands)
June 30, 1998 December 31, 1997
------------- -----------------
Finished Goods $2,396 $ 789
Work in Process 654 263
Raw Materials 2,059 1,404
------ ------
$5,109 $2,456
====== ======
8
9
NOTE 3 - Debt
Borrowings under long-term debt consist of the following at June 30, 1998
and December 31, 1997.
(Amounts in thousands)
--------------------------
1998 1997
-------- --------
Convertible debentures $ 28,300 $ 2,500
Subordinated primissory notes 62 1,125
Other 2,063 5,890
-------- --------
30,425 9,515
Less current maturities (300) (7,525)
-------- --------
$ 30,125 $ 1,990
======== ========
NOTE 4 - Contingencies
The Company currently is a defendant in several lawsuits involving
product liability claims. The Company's insurance carriers have assumed the
defense for all product liability and other actions involving the Company. The
final outcome of these lawsuits cannot be determined at this time, and
accordingly, no adjustment has been made to the consolidated financial
statements.
The Company is currently a defendant in a lawsuit claiming breach of
its obligations under a joint venture agreement with the plaintiff concerning
development and sale of a single product. The plaintiff is seeking monetary
damages of $20,000,000. The Company believes that the allegations contained in
the lawsuit are without basis in fact. As this lawsuit is in the preliminary
stages, the final outcome cannot be determined at this time and, accordingly, no
adjustment has been made to the Company's consolidated financial statements.
Note 5 - Comprehensive Income
The Company adopted the provisions of Statement of Financial
Accounting Standards No. 130 (SFAS 130), Reporting Comprehensive Income, in the
first quarter of 1998, which requires companies to disclose comprehensive income
separately of net income from operations. Comprehensive income is defined as the
change in equity during the period from transactions and other events and
circumstances from non-ownership sources. It includes all changes in equity
during a period, except those resulting from investments by owners and
distributions to owners. The adoption of this statement had no effect on the
Company for the six months ended June 30, 1998 or 1997.
9
10
HALSEY DRUG CO., INC. AND SUBSIDIARIES
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
Six months ended June 30 Three months ended June 30
--------------------------------------- ---------------------------------------
Percentage Percentage
Change Year- Change Year
to-Year to-Year
Increase Increase
(decrease) (decrease)
Percentage of Net Sales 1998 as Percentage of Net Sales 1998 as
----------------------- compared to ----------------------- compared to
1998 1997 1997 1998 1997 1997
------ ------ ----------- ------ ------ -----------
Net Sales ......................... 100.0 100.0 (18.5) 100.0 100.0 (0.5)
Cost of goods sold ................ 152.8 145.6 (14.5) 133.2 147.1 (9.0)
------ ------ ----- ------ ------ ------
Gross profit(loss) ............. (52.8) (45.6) (5.6) (33.2) (47.1) (29.2)
Research & Development ............ 10.9 9.6 (6.4) 10.4 14.4 (27.4)
Selling, general and administrative
expenses........................... 77.9 53.0 19.6 73.0 55.3 32.7
------ ------ ----- ------ ------ ------
Loss from Operations ........... (141.7) (108.2) 6.7 (116.6) (116.8) 0.3
Other income ...................... 47.8 -- -- 3.0 -- --
Interest expense, net ............. 23.5 10.7 80.4 23.9 12.5 91.7
------ ------ ----- ------ ------ ------
Loss before income taxes ...... (117.4) (118.9) (19.5) (137.5) (129.4) 6.9
------ ------ ----- ------ ------ ------
Provision for income taxes ........ -- -- -- -- -- --
------ ------ ----- ------ ------ ------
Net loss (117.4) (118.9) (19.5) (137.5) (129.4) 6.9
====== ====== ===== ====== ====== ======
10
11
SIX MONTHS ENDED JUNE 30, 1998 VS. SIX MONTHS ENDED JUNE 30, 1997
Net Sales
The Company's net sales for the six months ended June 30, 1998 of
$4,116,000 represents a decrease of $936,000 (18.5%) as compared to net sales
for the six months ended June 30, 1997 of $5,052,000. This decrease is a result
of a lack of sufficient working capital necessary to purchase raw materials.
Additionally, certain raw materials were in short supply and could not be
obtained. Without adequate inventory, the Company was unable to effectively
market its products.
Cost of Goods Sold
For the six months ended June 30, 1998, cost of goods sold of
$6,290,000 decreased as compared to the six months ended June 30, 1997 of
$7,355,000. This is attributable to a reduction in sales combined with certain
reductions in manufacturing costs primarily in direct and indirect labor. Gross
margin as a percentage of sales for the six months ended June 30, 1998 was
(52.8%) as compared to (45.6)% for the six months ended June 30, 1997. This is
attributable to a reduction in sales.
Selling, General and Administrative Expenses
Selling, general and administrative expenses as a percentage of
sales for the six months ended June 30, 1998 and 1997 were 77.9% and 53.1%,
respectively. The increase is due to additional personnel costs primarily in
regulatory and sales as well as increased legal expenses.
Research and Development Expenses
Research and development expenses as a percentage of sales for the
six months ended June 30, 1998 and 1997 were 11.0% and 9.6%, respectively. The
Company's research and development program continues to concentrate its efforts
toward the submission of new products to the FDA. The Company currently has
three Abbreviated New Drug Applications (ANDA's) on file with the FDA and
anticipates filing an additional seven ANDA's before the year end.
Net Earnings (Loss)
For the six months ended June 30, 1998, the Company had net loss of
$4,835,000 as compared to a net loss of $6,005,000 for the six months ended June
30, 1997. Included in results for the six months ended June 30, 1998 is other
income of $1,900,000 that had been recorded in September, 1997 as a deferred
gain on the sale of certain assets to Mallinckrodt Chemical Products, Inc.
("Mallinckrodt"). This transaction contained certain future requirements that
were met in the first quarter of 1998.
11
12
THREE MONTHS ENDED JUNE 30, 1998 VS THREE MONTHS ENDED JUNE 30, 1997
Net Sales
The Company's net sales for the three months ended June 30, 1998 of
$2,221,000 represents a increase of $12,000 (0.5%) as compared to net sales for
the three months ended June 30, 1997 of $2,209,000.
Cost of Goods Sold
For the three months ended June 30, 1998, cost of goods sold
decreased by approximately $292,000 as compared to the three months ended June
30, 1997. The decrease for 1998 is attributable to a reduction in certain
manufacturing costs primarily direct and indirect labor.
Selling, General and Administrative Expenses
Selling, general and administrative expenses as a percentage of
sales for the three months ended June 30, 1998 and 1997 were 73.0% and 55.3%,
respectively. The increase is due to additional personnel costs primarily in
regulatory and sales as well as increased legal expenses.
Research and Development Expenses
Research and development expenses as a percentage of sales for the
three months ended June 30, 1998 and 1997 was 10.4% and 14.4%, respectively. The
Company's research and development program continues to concentrate its efforts
toward the submission of new products to the FDA. The Company currently has
three Abbreviated New Drug Applications (ANDA's) on file with the FDA and
anticipates filing an additional seven ANDA's before the year end.
Net Earnings (Loss)
For the three months ended June 30, 1998, the Company had a net loss
of $3,054,000 as compared to a net loss of $2,858,000 for the three months ended
June 30, 1997. This increase is attributable to additional selling, general and
administrative costs as well as higher interest costs associated with the 5%
convertible debentures issued in 1998.
Year 2000 Issue
The "Year 2000" date conversion issue is the result of computer
programs being written using two digits rather than four digits to define an
applicable year within a computer system. The Company has recently conducted a
review of its computer systems and in conjunction with a program to perform an
overall upgrade of its management and accounting computer systems, has installed
new hardware and software that will function properly with respect to the Year
2000 Issue. Management has estimated the cost of this overall program to be
approximately $160,000 which is expected to be completed during the fiscal year.
Liquidity and Capital Resources
At June 30, 1998, the Company had cash and cash equivalents of
$3,614,000 as compared to $26,000 at December 31, 1997. The Company had a
working capital deficiency at June 30, 1998 of $293,000 and $22,716,000 at
December 31, 1997.
On March 10, 1998, the Company completed a private offering of
securities. The securities issued in the Offering consisted of 5% convertible
senior secured debentures and common stock purchase warrants exercisable for an
aggregate of 4,202,020 shares of the Company common stock. The net proceeds to
the Company from the Offering, after the deduction of related Offering expenses,
was approximately $19.6 million. In addition, in accordance with the terms of
the Debenture and Warrant Purchase Agreement pursuant to which the Offering was
completed, the Company granted the Galen Investor Group an option to invest an
additional $5 million in the Company at any time within eighteen months from the
date of the closing of the Offering in exchange for Debentures and Warrants
having terms identical to those issued in the Offering (the "Galen Option"). In
June 1998, the
12
13
Galen Investor Group exercised this option.
The net proceeds of the Offering have, in large part, been used to
satisfy a substantial portion of the Company's liabilities and accounts payable.
Such liabilities include the full satisfaction of the Company's Bank
indebtedness and related fees, payment to the landlord of the Brooklyn facility
and satisfaction of outstanding judgements and liens. Such repayments have
allowed the Company to avoid the threatened foreclosure sale by its Banks of the
Indiana facility securing such indebtedness. Additionally, pursuant to
agreements reached with other large creditors in anticipation of the completion
of the Offering, including the Company's landlord and the Department of Justice,
the Company has been able to bring these creditors current and is in compliance
with installment payment agreements providing favorable terms to the Company.
Satisfaction of the Company's current obligations to its landlord of the
Brooklyn facility for accrued and unpaid rent, penalties and expenses has
allowed the Company to renegotiate its lease and avoid eviction. The Offering
proceeds has also allowed the Company to satisfy its outstanding state and
Federal payroll tax obligations and meet current payroll tax obligations.
The net proceeds from the exercise of the Galen Option have been
used, in large part, to fund working capital, including the purchase of raw
materials, payroll expenses and other Company expenses.
In addition to the net proceeds from the exercise of the Galen
Option, the Company has secured bridge financing from Galen Partners III, L.P.,
Galen Partners International III, L.P and Galen Employee Fund III, L.P.
(collectively, the "Galen Group") in the amount of up to $1,000,000, having a
term of 90 days (the "Bridge Loan"). The Bridge Loan bears interest at 10% per
annum and is secured by a first lien on all of the Company's assets. In
consideration for the Bridge Loan, the Company issued seven-year warrants to the
Galen Group to purchase an aggregate of 50,000 shares of the Company's common
stock at an exercise price of $2.31 per share. The Warrants are substantially
identical to those issued in the Offering.
The Bridge Facility was secured by the Company in order to provide
necessary working capital pending the Company's obtaining a secured line of
credit from a banking institution. The Company is in the process of negotiating
with a banking institution to secure a $10 million line of credit. There can be
no assurance, however, that the Company will be able to obtain such financing on
commercially acceptable terms. In the event the Company were unsuccessful in
obtaining such financing, the Company would be required to explore other sources
of working capital, including the issuance of debt and/or equity securities or a
joint venture or other marketing alliance. No assurance can be given that such
sources of working capital could be secured on acceptable terms, if at all.
Failure to obtain a line of credit or alternative sources of financing in the
near term will materially adversely affect the Company's working capital
position and financial condition and results of operations.
13
14
PART II OTHER INFORMATION
Item 1. Legal Proceedings
The Company has been named as a defendant in a complaint filed with
the United States District Court, Eastern District of New York on June 30, 1998
(the "Complaint") by Quality Products & Services, L.L.C. The Complaint alleges
the existence of a Joint Venture Agreement between the Plaintiff and the Company
concerning the development, manufacturing and marketing of a single product. The
Complaint also alleges that the Company has breached the Agreement by failing to
satisfy its respective obligations defined in the Agreement. The Complaint seeks
monetary damages of approximately $20 million. The Company believes that the
allegations contained in the Complaint are without basis in fact, and that it
has meritorious defenses to each of the allegations. The Company has retained
counsel and intends to vigorously defend this action and to date has filed an
Answer and Counterclaim to the Complaint.
Item 2. Changes in Securities and Use of Proceeds
On March 10, 1998, the Company consummated a private offering of
securities for an aggregate purchase price of $20.8 million (the "Offering").
The securities issued in the Offering consisted of 5.0% convertible senior
secured debentures (the "Debentures") and common stock purchase warrants (the
"Warrants") exercisable for an aggregate of 4,202,020 shares of the Company's
common stock, $.01 par value per share (the "Common Stock"). The Debentures and
Warrants were issued by the Company pursuant to a certain Debenture and Warrant
Purchase Agreement dated March 10, 1998 (the "Purchase Agreement") by and among
the Company, Galen Partners III, L.P., Galen Partners International III, L.P.,
Galen Employee Fund III, L.P. (collectively 'Galen") and each of the Purchasers
listed on the signature page thereto (inclusive of Galen, collectively, the
"Galen Investor Group").
In accordance with the terms of the Purchase Agreement, the Company
granted the Galen Investor Group an option to invest an additional $5 million in
the Company at any time within eighteen months from the date of the closing of
the Offering in exchange for debentures and warrants having terms identical to
those issued in the Offering (the "Galen Option"). During June 1998, the Galen
Investor Group exercised its option resulting in the issuance by the Company of
5% convertible senior secured debentures in the principal amount of $5 million
and 1,010,100 warrants, 505,050 of which are exercisable at $1.50 per share and
505,050 of which are exercisable at $2.375 per share.
Each of the Purchasers comprising the Galen Investor Group were
accredited investors as defined in Rule 501(a) of Regulation D promulgated under
the Securities Act of 1933, as amended (the "Act"). The Debentures and Warrants
issued in the Offering and pursuant to the Galen Option were issued without
registration under the Act in reliance upon Section 4(2) of the Act and
Regulation D promulgated thereunder.
Reference is made to the Company's Current report on Form 8-K as
filed with the Securities Exchange Commission on March 24, 1998 for a
description of the terms and provisions of the Debentures, the Warrants and the
Purchase Agreement.
14
15
Item 4. Submission of Matters to a Vote of Security Holders.
The Company's 1998 Annual Meeting of Shareholders was held on
Tuesday, June 30, 1998 for the following purposes:
1. To elect eight directors to the Company's Board of
Directors to hold office until the 1999 Annual Meeting
of Shareholders ("Proposal 1");
2. To authorize an amendment to the Company's Certificate
of Incorporation (the "Charter") to increase the number
of authorized shares of its common stock from 20,000,000
share to 40,000,000 shares ("Proposal 2");
3. To authorize an amendment to the Company's Charter to
entitle the holders of the Company's 5% convertible
senior secured debentures due March 15, 2003 to vote on
all matters submitted to a vote of shareholders of the
Company, voting together with holders of common stock as
one class ("Proposal 3");
4. To adopt the Company's 1998 Stock Option Plan ("Proposal
4"); and
5. To ratify the appointment of Grant Thornton LLP as
independent auditors of the Company for the fiscal year
ending December 31, 1998 ("Proposal 5").
The voting as to each Proposal was as follows:
PROPOSAL 1
Name For Withheld
---- --- --------
William Skelly 11,072,281 111,697
Michael K. Reicher 11,072,281 111,697
Alan J. Smith, Ph.D. 11,072,281 111,697
William A. Sumner 11,072,281 111,697
Bruce F. Wesson 11,072,281 111,697
Srini Conjeevaram 11,072,281 111,697
Zubeen Shroff 11,072,281 111,697
Peter A. Clemens 11,072,281 111,697
PROPOSAL 2
For Against Abstain
--- ------- -------
10,995,171 167,308 21,499
PROPOSAL 3
For Against Abstain Broker Non-Votes
--- ------- ------- ----------------
7,848,540 135,490 26,444 3,172,504
15
16
PROPOSAL 4
For Against Abstain Broker Non-Votes
--- ------- ------- ----------------
7,538,114 440,332 33,028 3,172,504
PROPOSAL 5
For Against Abstain
--- ------- -------
11,142,106 16,861 25,011
Item 6. Exhibits and Reports on Form 8-K.
(a) Exhibits. The exhibits required to be filed as part of this
report on Form 10-Q are listed in the attached Index.
(b) Reports on Form 8-K. None.
16
17
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
HALSEY DRUG CO., INC.
Date: August 13, 1998 BY: /s/Michael K. Reicher
-----------------------
Michael K. Reicher
President and Chief
Executive Officer
Date: August 13, 1998 BY: /s/ Peter A. Clemens
-----------------------
Peter A. Clemens
Vice President and
Chief Financial Officer
17
18
EXHIBIT INDEX
Exhibit Description
No.
27 Financial Data Schedule, which is submitted
electronically to the Securities and Exchange Commission
for information only and not filed.
18
5
1,000
6-MOS
DEC-31-1998
JUN-30-1998
3,614
0
977
50
5,109
9,810
18,617
13,919
18,218
10,103
0
0
0
142
(22,152)
18,218
4,116
4,116
6,290
6,290
3,658
0
969
(4,835)
0
(4,835)
0
0
0
(4,835)
(0.35)
(0.35)
